Navigation Links
Broad Spectrum Antibiotic Available for Antibiotic Resistant Bacteria

Tygacil (tigecycline)is a new, expanded broad-spectrum IV antibiotic that can be used for the treatment of a wide range of infections including those caused by antibiotic// resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). It will be available in the UK from today. Availability of this new antibiotic comes at a time when the need for effective new treatments is greater than ever and clinicians are running out of options.

"Difficult to treat, antibiotic-resistant and often life-threatening infections are a growing problem in the UK, costing the NHS an estimated additional £1 billion annually," says Dr Robert Masterton, Executive Medical Director and Consultant Microbiologist, NHS Ayrshire & Arran, "Even more worrying has been the emergence of the organisms commonly called 'superbugs' – those very worrying bacteria that have become resistant to a large number and in some cases all available antibiotics. Add to this the diminishing development of new antibiotics in the last 20 years and we could soon see a return to the Florence Nightingale era where infections caused more death than bullets because there were no effective drugs to treat these diseases. The introduction of tigecycline in the UK comes at absolutely the right time and will provide a vital new weapon in the fight against infection."

Tigecycline has been licensed for use in the UK as a treatment for a variety of complicated skin and soft tissue infections including infected wounds and complicated intra- abdominal infections such as complicated appendicitis.1 It is the world's first glycylcycline and has been developed by Wyeth to overcome two common mechanisms of resistance that have reduced the efficacy and limited the use of certain existing antibiotics.

While MRSA has received wide media and government attention and concern in the UK, other infections like Escherichia Coli (E. Coli) and Klebsiella could pose an even greater risk to public health.4, 5 Tigecycline is one of a few new antibiotics with measured activity against these bacteria6 and there are few other antibiotics with a similar spectrum of activity expected this decade.

"Until now, the lack of available antibiotic options for these more difficult to treat bacteria has necessitated the use of combination therapies – two or more different antibiotics – to fight the resistant bacteria," explains Dr Mark Palazzo, Chief of Service for Critical Care Medicine at Hammersmith Hospitals NHS Trust, "Combination treatment can contribute to increased drug costs, drug interactions, with potentially higher patient risk and further increased antibiotic resistance which complicates the treatment. It would be an advantage for patient care to have the option of a new single effective therapy" he concludes.

Serious infections treated in the hospital are a major cause of morbidity and death among hospitalised patients worldwide.7 In the UK alone, hospital-acquired infections (HAIs) account for a staggering 5,000 deaths per year.8 It is estimated that these infections affect just over 300,000 patients every year9 with about nine per cent of hospital patients having a HAI at any one time.

Tigecycline was licensed by the European Commission for use in Europe on 24th April 2006 and is available in the UK today. Tigecycline is indicated for the treatment of complicated infections of the skin and soft tissue and complicated intra-abdominal infections.1 Tigecycline is supported by comprehensive global in vitro studies and an in vivo clinical trials programme.

The most common adverse events reported in clinical trials with tigecycline were nausea and vomiting. These occurred early in the treatment and were generally mild or moderate in severity.

Source : Eurekaert
'"/>




Related medicine news :

1. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
2. Plan To Connect Remote Aboriginal Communities Through Broadband
3. Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc
4. FDA Announces Audio Broadcasts on Emerging Drug Safety Information
5. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
6. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
7. Lack Of Social Skills Linked To Autism Spectrum Disorder (ASD)
8. Fetal Alcohol Spectrum Disorder in Children Can Be Diagnosed With Eye Movement Tests
9. Younger Siblings of Children With Autism Spectrum Disorders Score Low
10. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
11. Antibiotics Helps Autism
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology: